Oscar Health OSCR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.65B+52.6% | $2.81B+17.3% | $2.99B+23.2% | $2.86B+29.0% | $3.05B+42.2% | ||
| $706.23M+46.3% | $511.03M+9.7% | $521.59M+13.3% | $534.49M+22.8% | $482.76M+22.5% | ||
| $7.02M+4.3% | $7.88M-14.7% | $7.31M-2.5% | $6.97M-8.3% | $6.73M-13.8% | ||
| $704.09M+137% | -$333.75M— | -$129.25M-167% | -$230.48M-440% | $297.12M+60.1% | ||
| 15.2%+5.4pp | -11.9%— | -4.3%-2.3pp | -8%-11.1pp | 9.8%+1.1pp | ||
| $5.38M-10.2% | $0-100% | $6.86M+17.9% | $5.85M-2.4% | $5.99M+1.6% | ||
| $71K+102% | -$20.03M— | -$3.18M-270% | $2.79M+420% | -$2.92M-148% | ||
| $698.77M+142% | -$352.68M— | -$139.29M-166% | -$233.54M-483% | $288.21M+61.5% | ||
| $19.75M+55.5% | $0— | -$1.81M-187% | -$5.05M-209% | $12.71M+1,176% | ||
| $679M+147% | -$352.61M— | -$137.45M-152% | -$228.36M-506% | $275.27M+55.2% | ||
| 14.6%+5.6pp | -12.6%— | -4.6%-2.4pp | -8%-10.5pp | 9%+0.8pp | ||
| $2.07+125% | -$1.34— | -$0.53-141% | -$0.89-545% | $0.92+48.4% | ||
| $711.1M+134% | -$325.87M— | -$121.94M-198% | -$223.51M-396% | $303.85M+57.1% | ||
| 15.3%+5.3pp | -11.6%— | -4.1%-2.4pp | -7.8%-11.2pp | 10%+0.9pp | ||
| $704.09M+137% | -$333.75M— | -$129.25M-167% | -$230.48M-440% | $297.12M+60.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Oscar Health's revenue?
- Oscar Health (OSCR) generated $13.3B in revenue over the trailing twelve months, up 31.9% year over year.
- Is Oscar Health profitable?
- Oscar Health is not currently profitable: it reported a net loss of $39.4M over the trailing twelve months, a -0.3% net margin.
- What is Oscar Health's earnings per share?
- Oscar Health's diluted EPS over the trailing twelve months is $-0.69.
- Where does Oscar Health's income statement data come from?
- Every line is extracted from Oscar Health's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
